Tailored Antibiotic Strategy Shortens Treatment for Left-Sided Infective Endocarditis, POET-II Study Finds

A new study, POET-II, presented at ESC Congress 2026 and simultaneously published in The New England Journal of Medicine, indicates that a clinical response-tailored antibiotic strategy can shorten antibiotic duration by two weeks for patients with left-sided infective endocarditis, without major safety concerns. Researchers randomized approximately 500 patients, demonstrating that shorter courses of antibiotics may improve patients' quality of life by reducing the physical and psychological toll of prolonged treatment and hospitalizations.

Context

Left-sided infective endocarditis is a severe condition that typically requires prolonged antibiotic treatment to manage effectively. Traditionally, patients have faced lengthy courses of antibiotics, which can lead to various complications and a decreased quality of life. The POET-II study involved around 500 patients and aimed to evaluate the effectiveness and safety of a tailored antibiotic strategy.

Why it matters

The findings from the POET-II study could significantly change the standard treatment for left-sided infective endocarditis, a serious heart infection. Shortening antibiotic treatment duration may enhance patient quality of life by minimizing the burden of lengthy therapies. This approach could also reduce healthcare costs associated with extended hospital stays and treatment.

Implications

If adopted widely, this strategy could lead to a shift in treatment protocols for infective endocarditis, benefiting both patients and healthcare systems. Patients may experience fewer side effects and improved overall well-being. Additionally, hospitals could see reduced patient loads and costs associated with prolonged treatments.

What to watch

Healthcare providers may begin to adopt the tailored antibiotic strategy based on the study's findings. Further guidelines and recommendations from medical organizations could emerge in the near future. Monitoring patient outcomes and experiences will be crucial as this new approach is implemented in clinical settings.